Liver Innovation Platform for Biotech Teams, Startup and Investors - The Liver Investor Network

The Liver Investor Network is an investor and partnering platform devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during Jerusalem meeting.

Come and present, discuss, exchange and initiate a collaboration with Israeli and international leaders and actors of liver world.

Startup and Biotech teams can present their innovations during a dedicated session “10 minutes to convince”

Small space will be also available to demonstrate and show your innovations.

Investors, private company,  pharma and Biotech industries will be invited to select the best project.

Targeting Liver Award 2015  

All projects will be evaluated by the scientific committee.  One award will be dedicated to the most innovative project.

The Winner will benefit with a large international communication, free participation to Targeting Liver 2015 and a financial support from our partners.

As example: The Liver Drugs of Tomorrow : NASH and More…

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. Many people live with fatty livers, but in some of them only, the fat causes chronic inflammation of the liver - fibrosis - cirrhosis - liver failure and death. The disease is called Nonalcoholic Steatohepatitis because its complications are similar to the liver disease that is caused by long-term, heavy alcohol drinking, but without being alcohol abusers. Currently there are no approved drugs to treat NASH. Studies have shown that over a ten year period, at least 10% of NASH patients will develop cirrhosis. Liver-related mortality due to NASH is ten-fold that of the general population. Recent studies estimate that approximately 12% of the U.S. adult population has NASH, while 2.7% (potentially more than six million patients) are believed to have advanced liver fibrosis or cirrhosis due to progression of the disease. The proportion of liver transplants attributable to NASH has increased rapidly in past years, and over the next decade, the disease is projected to become the leading indication for liver transplant ahead of chronic hepatitis C and alcoholic liver disease.

If you are intersted by this opportunity, please don't hesitate to contact us.

For more information about Targeting Liver Diseases 2015: www.targeting-liver.com